Similar articles for PMID: 22739650

Year	Number of Results
1994	1
1996	2
1997	1
1998	1
1999	1
2000	1
2001	1
2002	3
2003	3
2004	2
2005	3
2006	5
2007	2
2008	6
2009	4
2010	7
2011	6
2012	7
2013	6
2014	5
2015	14
2016	17
2017	6
2018	7
2019	10
2020	3
2021	5
2022	7
2023	1
2024	0

1

Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer.

Petru E, Zeimet AG, Sevelda P, Seifert M, Singer C, Hubalek M, Angleitner-Boubenizek L, Speiser P, Benedicic C, Stummvoll W, Reinthaller A; Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO). Petru E, et al. Wien Klin Wochenschr. 2012 Jun;124(11-12):412-8. doi: 10.1007/s00508-012-0185-2. Epub 2012 Jun 28. Wien Klin Wochenschr. 2012. PMID: 22739650

2

Effects of primary granulocyte-colony stimulating factor prophylaxis on neutropenic toxicity and chemotherapy dose delivery in Chinese patients with breast cancer who received adjuvant docetaxel plus cyclophosphamide chemotherapy: a retrospective cohort study.

Kwok CCH, Wong WH, Chan LL, Wong SPY, Wang F, Wong MCS, Tse SLA. Kwok CCH, et al. Hong Kong Med J. 2022 Dec;28(6):438-446. doi: 10.12809/hkmj219439. Epub 2022 Oct 20. Hong Kong Med J. 2022. PMID: 36261264 Free article.

3

Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis in chemotherapy-induced febrile neutropenia among breast cancer and Non-Hodgkin's lymphoma patients under Taiwan's national health insurance system.

Wen TJ, Wen YW, Chien CR, Chiang SC, Hsu WW, Shen LJ, Hsiao FY. Wen TJ, et al. J Eval Clin Pract. 2017 Apr;23(2):288-293. doi: 10.1111/jep.12597. Epub 2016 Aug 4. J Eval Clin Pract. 2017. PMID: 27491287

4

Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?

Skedgel C, Rayson D, Younis T. Skedgel C, et al. Support Care Cancer. 2016 Jan;24(1):387-394. doi: 10.1007/s00520-015-2805-7. Epub 2015 Jun 17. Support Care Cancer. 2016. PMID: 26081595

5

Suboptimal duration of granulocyte colony-stimulating factor use and chemotherapy-induced neutropenia in women diagnosed with breast cancer.

Lin WT, Wen YW, Chien CR, Gau CS, Chiang SC, Hsiao FY. Lin WT, et al. Clin Ther. 2014 Sep 1;36(9):1287-94. doi: 10.1016/j.clinthera.2014.06.034. Epub 2014 Aug 15. Clin Ther. 2014. PMID: 25130388

6

Colony-stimulating factors for the management of neutropenia in cancer patients.

Dale DC. Dale DC. Drugs. 2002;62 Suppl 1:1-15. doi: 10.2165/00003495-200262001-00001. Drugs. 2002. PMID: 12479591 Review.

7

Defining the impact of the use of granulocyte colony stimulating factors on the incidence of chemotherapy-induced neutropenia in patients with gynecologic malignancies.

Julius JM, Hammerstrom A, Wei C, Rajesh R, Bodurka DC, Kurian S, Smith JA. Julius JM, et al. J Oncol Pharm Pract. 2017 Mar;23(2):121-127. doi: 10.1177/1078155215623084. Epub 2016 Jun 23. J Oncol Pharm Pract. 2017. PMID: 26692242

8

Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.

Link H, Nietsch J, Kerkmann M, Ortner P; Supportive Care Group (ASORS) of the German Cancer Society (DKG). Link H, et al. Support Care Cancer. 2016 Jan;24(1):367-376. doi: 10.1007/s00520-015-2779-5. Epub 2015 Jun 17. Support Care Cancer. 2016. PMID: 26081593

9

Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.

Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M. Renner P, et al. Cochrane Database Syst Rev. 2012 Oct 17;10:CD007913. doi: 10.1002/14651858.CD007913.pub2. Cochrane Database Syst Rev. 2012. PMID: 23076939 Free article. Review.

10

Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.

Nabholtz JM, Cantin J, Chang J, Guevin R, Patel R, Tkaczuk K, Vodvarka P, Lindsay MA, Reese D, Riva A, Mackey J. Nabholtz JM, et al. Clin Breast Cancer. 2002 Oct;3(4):268-75. doi: 10.3816/CBC.2002.n.030. Clin Breast Cancer. 2002. PMID: 12425755 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

110 results

Results by year